Skip to main content
Cenra Inc. logo

Cenra Inc. — Investor Relations & Filings

Ticker · 3716 ISIN · TW0003716007 TW Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2025-06-09 Transaction in Own Shar…
Country TW Taiwan
Listing TW 3716

About Cenra Inc.

https://www.cenra.com/

Cenra Inc. is a diversified healthcare enterprise with a history dating back to 1952. The company operates across a comprehensive value chain encompassing research and development, manufacturing, commercial marketing, and long-term care services. Its extensive portfolio includes active pharmaceutical ingredients (APIs), human pharmaceuticals, animal health products, and consumer health brands such as dietary supplements and personal care items. With a global reach spanning over 60 markets, the organization utilizes nine production bases and more than ten specialized technology platforms to deliver integrated health solutions. Cenra Inc. focuses on high-barrier oncology medications, complex generics, and 505(b)(2) drug developments. By integrating scientific innovation with rigorous operational management, the company provides accessible medical care and health services designed to meet evolving needs across all life stages.

Recent filings

Filing Released Lang Actions
公告本公司第2次買回庫藏股期間屆滿及執行情形
Transaction in Own Shares Classification · 100% confidence The document is a company announcement regarding the completion and execution details of a share buyback program (treasury stock repurchase). It includes specifics such as the number of shares bought back, total amount spent, average price, and reasons for incomplete execution. This type of document is a report on transactions involving the company's own shares, specifically a share repurchase activity. It is not a financial report, earnings release, or regulatory filing about financial results. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and content confirm it is a direct report of share repurchase activity, not an announcement of a report or a certification.
2025-06-09 Chinese
公告本公司114年度股東常會重要決議事項
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement from a listed company (3716 中化控股) regarding the important resolutions passed at the Annual General Meeting (AGM) held on 114/05/27 (Taiwanese calendar year). It lists decisions such as dividend distribution, amendments to company articles, approval of business reports and financial statements, capital increase plans, and other governance matters. The document is short (790 characters) and primarily reports the results of the shareholder meeting rather than providing the full report or detailed financial statements. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. Therefore, the correct classification is DVA with high confidence.
2025-05-27 Chinese
代重要子公司中國化學製藥股份有限公司辦理財產減資 致債權人公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (906 characters) from a listed company (3716 中化控股) regarding a capital reduction by its important subsidiary (中國化學製藥股份有限公司). It details the decision by the subsidiary's board to reduce capital, the amount and ratio of reduction, and the legal announcement to creditors. The document does not contain financial statements or detailed financial analysis but is a formal notification of a corporate action related to capital structure. It is not a full financial report, earnings release, or management discussion. It is also not a report publication announcement since it contains substantive information about the capital reduction event itself. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-05-26 Chinese
代重要子公司-中國化學製藥股份有限公司公告 董事會決議辦理財產減資
Capital/Financing Update Classification · 95% confidence The document is a short announcement (857 characters) from a listed company (3716 中化控股) reporting a board resolution regarding a capital reduction by an important subsidiary (中國化學製藥股份有限公司). It details the reduction amount, shares cancelled, and related dates. There is no financial statement or detailed report content, only a notification of a board decision on capital structure change. The document is not a full financial report but an update on capital changes. According to the definitions, this fits best under 'Capital/Financing Update (CAP)' which covers updates on company fundraising, financing activities, or capital structure changes. The document is not a report publication announcement or regulatory filing as it contains substantive information about the capital reduction decision itself.
2025-05-26 Chinese
114年第1季大陸投資
Regulatory Filings Classification · 90% confidence The document is a detailed tabular disclosure of investment amounts and related financial data concerning investments in mainland China by a Taiwanese listed company, 中化控股. It includes specific financial figures, investment methods, and regulatory approval limits. The content is focused on investment details rather than a full financial report or earnings announcement. The document length is 1818 characters, which is relatively short and does not appear to be a full annual or interim report. It is not a simple announcement or certification but a detailed investment disclosure. This type of document aligns best with Regulatory Filings (RNS), as it is a regulatory disclosure of investment information that does not fit into other specific categories like Annual Report, Interim Report, or Capital/Financing Update.
2025-05-14 Chinese
114年第1季海外子公司投資
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure related to investment holdings in overseas subsidiaries for the first quarter of the 114th year (likely a fiscal period). It contains tabulated data on shareholding percentages, original investment amounts, investment balances, and recognized investment gains or losses. The document length is very short (830 characters), and it appears to be a regulatory disclosure of investment holdings rather than a full financial report or detailed analysis. There is no indication of a full annual or interim report, audit report, or earnings release. The content fits best with a regulatory filing or general compliance disclosure rather than a detailed report. Given the short length and nature of the content, the most appropriate classification is Regulatory Filings (RNS).
2025-05-14 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.